A venture capital-backed antibody company called Argen-x BV has raised €9.5 million in a Series A financing round from a syndicate of investors, co-led by Forbion Capital Partners and Life Sciences Partners, both of the Netherlands.
Regulators who strive to ensure the safety of medicines sometimes give different advice to companies developing drugs than do health technology assessment (HTA) bodies that rule on the cost effectiveness of the same drugs.
Arpida Ltd and Evolva SA have announced plans to merge to create a larger, publicly-listed biotechnology company with a pipeline of drug candidates as well as revenue-generating discovery partnerships.
Osiris Therapeutics Inc said that preliminary results from two Phase 3 trials of its stem cell treatment for acute graft-versus-host disease (GvHD) did not reach their primary endpoints.
Scientists from the UK and France have identified three genes that appear to increase a person’s chances of developing Alzheimer’s disease, the most common cause of dementia.
ProFibrix BV of the Netherlands has raised €8 million in a Series B round enabling it to carry forward plans to seek FDA authorisation for a combined Phase 2/3 trial in the US of its candidate tissue sealant for use in surgery or trauma injury, Fibrocaps.
Elan Corporation Plc said that it will work quickly to resolve objections by a US court to its proposed strategic alliance with Johnson & Johnson that would recapitalise the company and give it the resources to commercialise its pipeline.
Researchers from industry and two non-profit organisations have reported the discovery of two new broadly neutralising antibodies against the human immunodeficiency virus (HIV), thus advancing the goal of developing an AIDS vaccine.
An investor in Celsis International Plc is on the verge of success in acquiring the drug toxicity detection company whose shares are listed on the London Stock Exchange. The investor is North Atlantic Value LLP (NAVLLP), part of the JO Hambro Capital Management Group.